A fatal colchicine ingestion with antemortem blood concentration - McCabe DJ, Wilson BZ, Radke JB, Bottei EM.
Although there are multiple therapeutic uses for colchicine, it is particularly dangerous in the setting of overdose due to an irreversible mechanism of action combined with a narrow therapeutic window. Colchicine is an antimitotic agent that binds tubulin... (Source: SafetyLit)
Source: SafetyLit - April 4, 2022 Category: International Medicine & Public Health Tags: Poisoning Source Type: news

Coronavirus (COVID-19): evidence relevant to acute and critical care, Cochrane Library (updated 22nd March 2022)
Updated 22 March 2022 to expand the title and scope of the collection from ' evidence relevant to critical care ' to ' evidence relevant to acute and critical care ' ; to add two Cochrane Clinical Answers to the review ' Colchicine for the treatment of COVID-19 ' ; and to add the new review ' Inhaled corticosteroids for the treatment of COVID-19 ' and its associated Cochrane Clinical Answer. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 31, 2022 Category: Consumer Health News Source Type: news

Palliative Care in Assisted Living
Mrs. M is a 92-year-old woman residing in an assisted living community. Her medical history includes hypertension, gout, hyperlipidemia, atrial fibrillation, hypothyroidism, and melanoma with invasion into the parotid gland; she has had removal of a lesion and a parotidectomy with nerve involvement impacting the 7th cranial nerve. Her medications include oral levothyroxine, 100 μg daily; oral vitamin D, 1,000 units daily; oral probenecid 500/colchicine, 0.5 mg daily; oral lisinopril, 5 mg daily; oral furosemide, 20 mg daily; oral duloxetine, 60 mg for depression; oral carvedilol, 6.25 mg twice a day; oral aspirin, 81 mg d...
Source: Caring for the Ages - March 29, 2022 Category: Health Management Authors: Barbara Resnick, Paige Hector Tags: Interdisciplinary Team Case Studies Source Type: news

Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial, BJGP
Primary analysis model (n=2755) found colchicine did not improve time to recovery vs. usual care in people at higher risk of complications with COVID-19 in the community (HR 0.919;95% CI 0.72-1.16), with~increase of 1.4 days in median time to self-reported recovery for colchicine (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 25, 2022 Category: Consumer Health News Source Type: news

Colchicine for the treatment of COVID19, Cochrane Library
Review (4 RCTs; n=16,013) found colchicine probably has little to no influence on mortality or clinical progression in people hospitalised with moderate to severe COVID ‐19; there is uncertainty about the evidence of its effect in those with asymptomatic infection or mild disease. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 7, 2022 Category: Consumer Health News Source Type: news

COVID-19 rapid guideline: managing COVID-19 [NG191], NICE (updated 1st December 2021)
This guideline covers the management of COVID-19 for children, young people and adults in all care settings. It brings together our existing recommendations on managing COVID-19, and new recommendations on therapeutics, so that healthcare staff and those planning and delivering services can find and use them more easily. We are continually monitoring the evidence and updating the guideline as new information emerges. On 1 December, we updated existing recommendations on colchicine. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 2, 2021 Category: Consumer Health News Source Type: news

' Misleading' Results in Colchicine COVID-19 Trials Meta-Analysis'Misleading' Results in Colchicine COVID-19 Trials Meta-Analysis
In a meta-analysis of six studies evaluating colchicine as a COVID-19 treatment, the anti-inflammatory drug for acute gout attacks did not appear to improve outcomes for patients.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - November 23, 2021 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news

Anti-inflammatory drug used to treat gout does NOT prevent hospitalization or death from COVID-19
A study performed by an Indian research team finds that the gout drug colchicine does not have the ability to reduce the risk of severe complications from COVID-19. (Source: the Mail online | Health)
Source: the Mail online | Health - November 22, 2021 Category: Consumer Health News Source Type: news

Corrigendum to: Pathogenic characteristics and treatment in 43 cases of acute colchicine poisoning - Lu X, Liu Y, Wang C, Dong J, Bai L, Zhang C, Zhang R, Sun C, Qiu Z.
[This corrects the article DOI: 10.1093/toxres/tfab074.]. In the original publication of this article, there were errors within the data of Table 1. Language: en... (Source: SafetyLit)
Source: SafetyLit - November 8, 2021 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Gloperba (Colchicine Oral Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 1, 2021 Category: Drugs & Pharmacology Source Type: news

Featured review: Colchicine for Covid
Is colchicine an effective treatment for people with COVID-19?Colchicine was debated to be a potential treatment option for COVID-19, hoping that the medication ’s anti-inflammatory properties could prevent or reduce a dysregulated immune response.Although there are completed studies without publication and diverse ongoing studies that could change our findings, the current evidence taken from 3 studies is moderate that colchicine makes no difference for people with moderate to severe disease. The safety of the medication remained unclear- given the restricted dosage range and the inconsistent reporting of (serious) adve...
Source: Cochrane News and Events - September 30, 2021 Category: Information Technology Authors: Lydia Parsonson Source Type: news

Gout Pharmacotherapy in Cardiovascular Diseases Gout Pharmacotherapy in Cardiovascular Diseases
This review examines the utility of current gout therapies in the treatment and prevention of cardiovascular disease, including allopurinol, febuxostat, and colchicine.American Journal of Cardiovascular Drugs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 30, 2021 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Two Swings, Two Misses With Colchicine, Vascepa in COVID-19 Two Swings, Two Misses With Colchicine, Vascepa in COVID-19
The study cohorts varied from healthcare and public workers at high risk for infection to individuals already hospitalized with COVID-19.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 1, 2021 Category: Consumer Health News Tags: Cardiology News Source Type: news

Colchicine Effective Regardless of ACS History, Timing: LoDoCo2 Colchicine Effective Regardless of ACS History, Timing: LoDoCo2
The results contrast with those from another subanalysis, in which greater benefits were observed with earlier administration of the repurposed gout medication.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 23, 2021 Category: Neurology Tags: Cardiology News Source Type: news

Pathogenic characteristics and treatment in 43 cases of acute colchicine poisoning - Lu X, Liu Y, Wang C, Dong J, Bai L, Zhang C, Zhang R, Sun C, Qiu Z.
Colchicine poisoning is complicated and has a high mortality rate. The aim of this study was to identify the pathogenic characteristics of colchicine poisoning cases and to propose a comprehensive treatment procedure. A total of 43 patients were divided in... (Source: SafetyLit)
Source: SafetyLit - August 23, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news